Background: Anxiety symptoms are common in patients with major depressive disorder (MDD) and are associated with greater severity, impaired functioning, and less favorable outcomes. The objective of this open-label study was to explore the effects of adjunctive brexpiprazole in patients with MDD and anxiety symptoms (NCT02013531). Methods: Patients with MDD and anxiety symptoms (HAM-A≥20) with an inadequate response to current ADT were enrolled and received open-label ADT+brexpiprazole 1 to 3mg/day (2mg/day target dose) for 6 weeks. Efficacy endpoints included change in clinician-rated MADRS and HAM-A total score from baseline TRD 2 or higher, treatment resistant depression, defined by history of two or more treatment failures to standard antidepressant therapy within the current depressive episode.
Abstracts | 55 to Week 6, and change in the 92-item patient-rated Kellner Symptom Questionnaire (KSQ, range 0 to 92) total score from baseline to Week 6. Results: A total of 37 patients were treated with brexpiprazole+ADT, of these 32 patients completed 6 weeks of treatment. Improvements were observed for the LS mean change in MADRS total score from Baseline to Week 6 in patients treated with brexpiprazole+ADT (least square mean change: -19.6) and in HAM-A total score (-17.8). In addition, the mean change from Baseline to Week 6 in KSQ total score (-29.4) also improved. Adjunctive brexpiprazole was well tolerated; the incidence of activating adverse events (akathisia, restlessness, agitation, anxiety, and insomnia) was low (≤5%); and no clinically relevant changes in the mean laboratory test values, vital signs, or ECG parameter values were observed. Conclusion: Adjunctive treatment with brexpiprazole may represent a novel and effective strategy for treatment of patients with MDD and symptoms of anxiety showing an inadequate response to ADT.
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Efficacy and safety of brexpiprazole (OPC-34712) as adjunctive treatment in major depressive disorder: Meta-analysis of two pivotal studies Brexpiprazole is a serotonin-dopamine activity modulator that acts as a partial agonist at 5-HT1A and dopamine D2 receptors, and an antagonist at 5-HT2A and noradrenaline alpha1B/2C receptors, all at similar potencies. The efficacy, safety and tolerability of adjunctive brexpiprazole were evaluated in patients with major depressive disorder (MDD) and inadequate response to antidepressant treatments (ADTs), based on pooled data from two pivotal phase III studies (NCT01360645 [1] ; NCT01360632 [2] ). Methods: Patients with MDD and inadequate response to 1-3 ADTs were enrolled and received single-blind ADT for 8 weeks. Patients with inadequate response after this prospective phase were randomized to ADT+brexpiprazole or ADT+placebo for 6 weeks. Both studies included fixed doses (2mg [Study 1: NCT01360645]; 1mg and 3mg [Study 2: NCT01360632]). Primary efficacy endpoint was the change in MADRS total score from baseline to Week 6. As the two studies had a similar design, a meta-analysis was performed with pooled placebo groups. Results: Adjunctive brexpiprazole showed greater improvement than adjunctive placebo in MADRS total score (least square mean difference to placebo+ADT [n=381]: 1mg+ADT [n=211]: -2.02, p=0.0018; 2mg+ADT [n=175]: -2.35, p=0.0007; 3mg+ADT [n=213]: -2.54, p=0.0001). The most frequent adverse events included akathisia (4.4%, 7.4%, 13.5%, 1.7%), weight increase (6.6%, 8.0%, 5.7%, 1.9%), tremor (4.0%, 2.1%, 5.2%, 2.2%) and somnolence (4.0%, 4.3%, 5.7%, 0.5%), in the brexpiprazole 1mg+ADT (n=226), 2mg+ADT (n=188), 3mg+ADT (n=229) and pooled placebo+ADT groups (n=411), respectively. Conclusion: Data from adequate and well-controlled clinical studies provide evidence that brexpiprazole is efficacious as adjunctive treatment in MDD patients with an inadequate response to ADTs. All doses of adjunctive brexpiprazole were well tolerated, with notably low levels of sedating or activating side effects.
